<?xml version="1.0" encoding="UTF-8"?>
<ref id="B196">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wald</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Corey</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Timmler</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Magaret</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Warren</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Tyring</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2014</year>). 
  <article-title>Helicase–primase inhibitor pritelivir for HSV-2 infection.</article-title>
  <source>
   <italic>N. Engl. J. Med.</italic>
  </source>
  <volume>370</volume>
  <fpage>201</fpage>–
  <lpage>210</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1301150</pub-id>
  <?supplied-pmid 24428466?>
  <pub-id pub-id-type="pmid">24428466</pub-id>
 </mixed-citation>
</ref>
